Congestion Continues In Private Label Mucinex Pipeline; Court Rules Against Mutual
This article was originally published in The Tan Sheet
A ruling for RB n Pennsylvania federal court comes as it girds for increased competition from additional guaifenesin expectorant formulations that are the equivalents of Mucinex brand products and that Perrigo is marketing under license from manufacturer Allergan.
You may also be interested in...
Mutual Pharmaceutical alleges in an antitrust suit that RB attempts to monopolize the extended-release guaifenesin OTC category with its Mucinex product. The suit says Mutual has lost “tens of millions” due to RB's failure to honor a contract to supply an “authorized generic” of the product.
Private equity partner takes Better Being helm; designer, Real Housewives star Heather Thomson invests in Hapbee; Full House stars talk bloating for P&G’s Align; changes in CRN membership development team lead; and Mara Renewables names CEO.
PDC Brands declines to provide support for nine challenged claims for Dr. Teal’s line of balms, lotions, oils, soaps, sprays and other topicals. It continues using those after halting use of 25 other similar claims challenged by P&G, marketer of melatonin-containing ZzzQuil.